

12-13-01

12/11/01

J1060 U.S. PTO

FORM PTO-1390 OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK	ATTORNEY'S DOCKET NUMBER <b>PF-0733 USN</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. <i>if known, see 37 CFR 1.5)</i> <b>10/018170</b> TO BE ASSIGNED
INTERNATIONAL APPLICATION NO. PCT/US00/16636	INTERNATIONAL FILING DATE 16 June 2000	PRIORITY DATE CLAIMED 16 June 1999	
TITLE OF INVENTION <b>INTRACELLULAR SIGNALING MOLECULES</b>			
APPLICANT(S) FOR DO/EO/US <b>YUE, Henry; TANG, Y. Tom; HILLMAN, Jennifer L.; LAL, Preeti; BANDMAN, Olga; BAUGHN, Mariah R.; AZIMZAI, Yalda; YANG, Junming; REDDY, Roopa, LU, Dyung Aina M.</b>			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is the <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).</li> <li><input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li><input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau)</li> <li><input type="checkbox"/> has been communicated by the International Bureau.</li> <li><input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li><input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</li> <li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))             <ol style="list-style-type: none"> <li><input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li><input type="checkbox"/> have been communicated by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input type="checkbox"/> have not been made and will not be made.</li> <li><input checked="" type="checkbox"/> attached hereto Article 34 Amendment</li> </ol> </li> <li><input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li><input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
<p><b>Items 11 to 16 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included.</li> <li><input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment, as follows:            Cancel in this application original claims #12, 14, 18, 20, 21, 23, 24, 25, 28-204 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims.  <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li><input type="checkbox"/> A substitute specification.</li> <li><input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li><input checked="" type="checkbox"/> Other items or information:             <ol style="list-style-type: none"> <li>Transmittal Letter (2 pp, in duplicate)</li> <li>Return Postcard</li> <li>Express Mail Label No.: <b>EL 856148931 US</b></li> <li>Sequence Listing Statement</li> </ol> </li> </ol>			

JC05 Rec'd GT/PTO 1 1 DEC 2001

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>TO BE ASSIGNED 10/018170</b>	INTERNATIONAL APPLICATION NO.: PCT/US00/16636	ATTORNEY'S DOCKET NUMBER PF-0733 USN
--	--	---

  

17. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..\$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$710.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	19 =	0	X \$ 18.00	\$	
Independent Claims	2 =	0	X \$ 80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
<b>SUBTOTAL</b>				\$710.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$710.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	
<b>TOTAL FEES ENCLOSED =</b>				\$710.00	
				Amount to be Refunded:	\$
				Charged:	\$

  

a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 09-0108 in the amount of \$710.00 to cover the above fees.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

INCYTE GENOMICS, INC.  
3160 Porter Drive  
Palo Alto, CA 94304

SIGNATURE

NAME: Diana Hamlet-Cox

REGISTRATION NUMBER: 33,302

DATE: 11 December 2001

Docket No.: PF-0733 USN

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, Washington, D.C. 20231

on 12-11-01  
By: Nancy Ramos  
Printed: NANCY RAMOS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Yue, et al.

Title: HUMAN INTRACELLULAR SIGNALING MOLECULES

PCT Serial No.: PCT/US00/16636

International Filing Date: 16 June 2000

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

---

Commissioner for Patents  
**BOX PATENT APPLICATION**  
Washington, D.C. 20231

**REQUEST TO PUBLISH APPLICATION WITH ARTICLE 34 AMENDMENTS**

Sir:

Applicants respectfully request that the present application be published under 35 U.S.C. § 122(b) with the claims as amended under PCT Article 34 on the attached substitute sheets, and which are submitted with the attached PCT application, rather than as originally filed.

Applicants submit that the Article 34 amendments should be considered as a part of the application as filed, as they were submitted in the form of replacement sheets during Chapter II examination of the PCT application, and should not be considered as a preliminary amendment which cannot be published unless submitted in electronic form.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 09-0108. This form is enclosed in duplicate.

Date: 11 Dec 2001

Respectfully submitted,  
INCYTE GENOMICS, INC.

Diana Hamlet-Cox

Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166